Company Overview (from transitiontherapeutics.com
Transition Therapeutics Inc. is a publicly traded biopharmaceutical company developing novel approaches and therapeutics for the treatment of diabetes, multiple sclerosis (MS) and restenosis. Using its proprietary technologies, Transition is focused on developing therapeutic innovations that inhibit the progression of these diseases as well as restore or normalize function.
Transition has developed lead therapies for its diabetes and MS programs. For the diabetes program, Transition focuses on the innovative Islet Neogenesis Therapy (I.N.T.TM) that offers a promising and exciting therapeutic alternative to insulin-dependent diabetics. For the MS program, Transition offers a novel and patented Interferon Enhancing Therapy (I.E.T.) that has been shown in two different animal models to be 2-5 times more effective than the current approved interferon therapy.
Founded in 1998, Transition has since made significant strides towards reaching its strategic objectives:
1. generating depth and value in its product development and its technologies
2. solidifying its financial position
3. building the necessary infrastructure, to succeed as a global biopharmaceutical player
For its diabetes program, Transition has completed two phase I clinical trials for its Islet Neogenesis Therapy lead product. For its MS program, Transition has completed a phase I clinical trial. |
